<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318509</url>
  </required_header>
  <id_info>
    <org_study_id>GMPower1</org_study_id>
    <nct_id>NCT04318509</nct_id>
  </id_info>
  <brief_title>Market Research - Acceptability Study for a New PKU Protein Substitute</brief_title>
  <official_title>Market Research - Acceptability Study for a New PKU Glycomacropeptide Based Protein Substitute (Dr Schär- Mevalia Amino Acids) Mevalia PKU GMPower - Vanilla</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Schär AG / SPA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Schär AG / SPA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate that a new protein substitute is acceptable and well
      tolerated in children with PKU.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Actual">May 19, 2019</completion_date>
  <primary_completion_date type="Actual">May 19, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal tolerance</measure>
    <time_frame>7 days</time_frame>
    <description>Questionnaire detailing any GI symptoms, severity and change from usual
• The collection of daily data about the gastro-intestinal tolerance of the protein substitute.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product compliance</measure>
    <time_frame>7 days</time_frame>
    <description>Daily questionnaire on amounts offered and amounts actually consumed, compared to recommended amount.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product palatability</measure>
    <time_frame>7 days</time_frame>
    <description>Questionnaire data captured to evaluate taste</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product acceptability</measure>
    <time_frame>7 days</time_frame>
    <description>Brief tick-box questionnaire on overall liking and acceptability of product</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>PKU</condition>
  <condition>Phenylketonurias</condition>
  <condition>Inborn Errors of Metabolism</condition>
  <condition>Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>PKU GMPOWER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GMPOWER</intervention_name>
    <description>(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years</description>
    <arm_group_label>PKU GMPOWER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PKU or PKU variant requiring a protein substitute.

          -  Subjects who were already taking a phenylalanine-free/low phenylalanine protein
             substitute and were willing to try the study product for 7 days.

          -  Patients aged 3 years of age to adulthood.

          -  Written informed consent obtained from participant or parental caregiver (as
             appropriate).

        Exclusion Criteria:

          -  Presence of serious concurrent illness

          -  Investigator's uncertainty about the willingness or ability of the patient to comply
             with the protocol requirements

          -  Participation in any other studies involving investigational or marketed products
             concomitantly or within two weeks prior to entry into the study.

          -  Any patients having taken antibiotics over the previous 2 weeks leading up to the
             study.

          -  Patients less than 3 years of age.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

